These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 31183356)

  • 1. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
    Zhang Y; He B; Zhou D; Li M; Hu C
    Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
    Pan G; Chen K; Yu X; Sheng J; Fan Y
    Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary resistance to osimertinib despite acquired
    Chang LK; Chang YL; Shih JY
    Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
    Yamaguchi F; Kato E; Wakabayashi A; Shikama Y
    Mol Clin Oncol; 2019 Aug; 11(2):127-131. PubMed ID: 31316771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
    Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
    Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A "triple whammy" in adenocarcinoma lung.
    Patro M; Gothi D; Vaidya S; Sah RB
    Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation.
    Chen J; Wu X; Wang J
    Front Oncol; 2022; 12():898586. PubMed ID: 35957876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
    Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
    Front Oncol; 2021; 11():621992. PubMed ID: 33718183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
    Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
    Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.